Overview


Factors which have been anticipated to boost the dementia associated with Alzheimer’s disease market growth includes growing geriatric population, a hike in the presence of Alzheimer’s disease on a scale, boost in the research and development expenditure and plenty of alternatives in treatment. In addition, an abundance of research and development endeavors in disease altering drugs and an augmentation in investment by major market players in clinical studies pertinent to enhanced treatment alternatives are instrumental in the expansion of the market size during the forecast time frame. Although, the exorbitant costs of the enhanced treatment facilities as well as the detrimental side-effects linked with specific treatments count as some of the reasons that may restrain the market growth.

Going by the segmentation of the drug class, the market is fragmented into memantine, combined drug (donepezil and memantine), cholinesterase/cholinergic, inhibitor and others. In the segment of cholinesterase/cholinergic inhibitor, it is to be observed this segment is controlling the market size of dementia associated with Alzheimer’s disease. This inhibitor, in value terms, is the first phase of treatment for AD and is a commonly prescribed drug for AD. This segment is predicted to experience considerable CAGR, in part, because of the positive attributes in the treatment of dementia ranging from mild to severe. At present, there is no known treatment that can alter the Alzheimer’s disease, and the treatments that does exist for AD relief are known as cholinesterase inhibitors.

The segment for memantine is estimated to grow at a considerable CAGR, due to the properties that it contains to treat AD that is moderate to severe.
With the distribution channel segment, it has been bifurcated into retail, hospital and online pharmacies. The hospital pharmacies are expected to capture significant market share during the forecast timeline owing to affordable medication. The online pharmacies is estimated to encounter high growth since there is an easy accessibility of drugs at the comfort of one’s home at a reduced rate.

  • Ono Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Allergan plc.
  • Merz Pharma GmbHCo. KGaA.
  • F. Hoffmann-La Roche Ltd
  • Daiichi Sankyo Company, Limited
  • Pfizer, Inc.
  • H. Lundbeck A/S.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Cholinergic/ Cholinesterase (ChE) Inhibitors
    • Donepezil
    • Galantamine
    • Rivastigmine
  • Memantine
    • Combined Drug (Memantine
    • Donepezil) and Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online Sales

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the dementia associated with Dementia Associated with Alzheimer?? Disease Market By Drug Class, By Distribution Channel and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Temporary Knee Spacers Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Temporary Knee Spacers Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Temporary Knee Spacers Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Dementia Associated with Alzheimer?? Disease Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cholinergic/ Cholinesterase (ChE) Inhibitors
         1.1. Donepezil
         1.2. Galantamine
         1.3. Rivastigmine
        2. Memantine
         2.1. Combined Drug (Memantine Donepezil) and Others

  • 8.   Global Dementia Associated with Alzheimer?? Disease Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail
        3. Online Sales

  • 9.   North America Dementia Associated with Alzheimer?? Disease Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Dementia Associated with Alzheimer?? Disease Market Analysis 2017-2022 and Forecast $yearF (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America $yearF

  • 11.   Europe Dementia Associated with Alzheimer?? Disease Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Dementia Associated with Alzheimer?? Disease Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Ono Pharmaceutical Co., Ltd.
         1.1. Company Overview (HQ, Business Segments, Employee Strength)
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Eisai Co., Ltd.
         2.1. Company Overview (HQ, Business Segments, Employee Strength)
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Johnson and Johnson Services, Inc.
         3.1. Company Overview (HQ, Business Segments, Employee Strength)
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Novartis AG
         4.1. Company Overview (HQ, Business Segments, Employee Strength)
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Allergan plc.
         5.1. Company Overview (HQ, Business Segments, Employee Strength)
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merz Pharma GmbHCo. KGaA.
         6.1. Company Overview (HQ, Business Segments, Employee Strength)
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. F. Hoffmann-La Roche Ltd
         7.1. Company Overview (HQ, Business Segments, Employee Strength)
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Daiichi Sankyo Company, Limited
         8.1. Company Overview (HQ, Business Segments, Employee Strength)
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Pfizer, Inc.
         9.1. Company Overview (HQ, Business Segments, Employee Strength)
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. H. Lundbeck A/S.
         10.1. Company Overview (HQ, Business Segments, Employee Strength)
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients